Biogen reports PML case

AMERICAN pharmaceutical company Biogen has reported another case of rare brain disease PML in a patient using the multiple sclerosis drug Tysabri – which is co-owned by Dublin-based pharma, Elan.

For the past number of months, Biogen has been posting regular weekly updates on PML cases on its website – the disease being a potential side-effect in users of the Tysabri drug.

The latest case, confirmed by the Boston- based company on Friday night, concerned a patient who had already taken 34 dosages of the treatment.